TY  - JOUR
T1  - Glycosylation Should Be Treated as Pharmacology Rather Than Decoration in Computational Models of Natural Product Exposure, Recognition, Transport, and Bioactivity
A1  - Patrick O'Connor
A1  - Grace Murphy
A1  - Niamh Walsh
JF  - International Journal of Pharmaceutical And Phytopharmacological Research
JO  - Int J Pharm Phytopharmacol Res
SN  - 2250-1029
Y1  - 2025
VL  - 15
IS  - 5
DO  - 10.51847/DcBIjoO69G
SP  - 111
EP  - 119
N2  - Natural-product glycosides are frequently represented computationally as scaffold variants whose sugar residues can be removed, simplified, or treated primarily as modifiers of bulk physicochemical properties. That simplification is sometimes reasonable, but it can also erase pharmacologically consequential information. This conceptual article examines glycosylation as a state variable that can alter molecular conformation, chemical stability, gastrointestinal transformation, epithelial transport, systemic chemical identity, cellular exposure, and target recognition. The central argument is not that glycosylation has a uniform directional effect, but that the sugar, linkage, substitution pattern, and transformation context may determine which molecular species should actually be modeled. A proposed glycosylation-aware pharmacology framework therefore treats an administered glycoside, its aglycone, conjugates, and microbially or enzymatically generated products as context-dependent members of an exposure–recognition hypothesis rather than interchangeable structures.

The same logic extends to computation: topology-aware encodings, carbohydrate-sensitive force fields, explicit metabolite-state enumeration, and task-specific validation may be required when sugar chemistry governs the biological question. Conversely, aglycone-centered modeling remains defensible when presystemic conversion is dominant or the sugar does not materially alter exposure or recognition. The framework is intended to improve mechanistic discipline, not to establish a validated prediction rule. Its principal limitation is the heterogeneity of glycoside classes, transport systems, microbiomes, experimental models, and computational representations. Prospective matched glycoside–aglycone studies are required to determine when glycosylation materially changes prediction and lead interpretation.
UR  - https://eijppr.com/article/glycosylation-should-be-treated-as-pharmacology-rather-than-decoration-in-computational-models-of-na-tdwvbatiipdq9ac
ER  -